메뉴 건너뛰기




Volumn 7, Issue 6, 2006, Pages 456-461

Refractory overactive bladder in men: Update on novel therapies

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; BOTULINUM TOXIN A; CHOLINERGIC RECEPTOR BLOCKING AGENT; DARIFENACIN; DETROL LA; DITROPAN XL; MUSCARINIC RECEPTOR BLOCKING AGENT; OXYBUTYNIN; SACTURA; SOLIFENACIN; STEROID 5ALPHA REDUCTASE INHIBITOR; TAMSULOSIN; TOLTERODINE; TROSPIUM CHLORIDE;

EID: 33750518190     PISSN: 15272737     EISSN: 15346285     Source Type: Journal    
DOI: 10.1007/s11934-006-0054-5     Document Type: Article
Times cited : (5)

References (37)
  • 1
    • 0036186813 scopus 로고    scopus 로고
    • The standardization of terminology of lower urinary tract function: Report from the Standardisation Sub-committee of the International Continence Society
    • Abrams P, Cardozo L, Fall M, et al.: The standardization of terminology of lower urinary tract function: report from the Standardisation Sub-committee of the International Continence Society. Neurourol Urodyn 2002, 21:167.
    • (2002) Neurourol Urodyn , vol.21 , pp. 167
    • Abrams, P.1    Cardozo, L.2    Fall, M.3
  • 2
    • 0035725404 scopus 로고    scopus 로고
    • How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study
    • Milsom I, Abrams P, Cardozo L, et al.: How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 2001, 87:760-766.
    • (2001) BJU Int , vol.87 , pp. 760-766
    • Milsom, I.1    Abrams, P.2    Cardozo, L.3
  • 3
    • 0036930323 scopus 로고    scopus 로고
    • Long-term health-related quality of life of patients receiving extended-release tolterodine for overactive bladder
    • Kelleher C, Kreder K, Pleil A, et al.: Long-term health-related quality of life of patients receiving extended-release tolterodine for overactive bladder. Am J Manag Care 2002, 8:S616-S630.
    • (2002) Am J Manag Care , vol.8
    • Kelleher, C.1    Kreder, K.2    Pleil, A.3
  • 4
    • 0036172767 scopus 로고    scopus 로고
    • Quality-of-life impact of lower urinary tract symptom severity: Results from the Health Professionals Follow-up Study
    • Welch G, Weinger K, Barry MJ: Quality-of-life impact of lower urinary tract symptom severity: results from the Health Professionals Follow-up Study. Urology 2002, 59:245-250.
    • (2002) Urology , vol.59 , pp. 245-250
    • Welch, G.1    Weinger, K.2    Barry, M.J.3
  • 5
    • 0031444212 scopus 로고    scopus 로고
    • A neurologic basis for the overactive bladder
    • de Groat WC: A neurologic basis for the overactive bladder. Urology 1997, 50:36-52.
    • (1997) Urology , vol.50 , pp. 36-52
    • De Groat, W.C.1
  • 6
    • 0030667591 scopus 로고    scopus 로고
    • Smooth muscle of the bladder in the normal and the diseased state: Pathophysiology, diagnosis and treatment
    • Turner WH, Brading AF: Smooth muscle of the bladder in the normal and the diseased state: pathophysiology, diagnosis and treatment. Pharmacol Ther 1997, 75:77-110.
    • (1997) Pharmacol Ther , vol.75 , pp. 77-110
    • Turner, W.H.1    Brading, A.F.2
  • 7
    • 11144347007 scopus 로고    scopus 로고
    • The urothelium in overactive bladder: Passive bystander or active participant?
    • de Groat WC: The urothelium in overactive bladder: passive bystander or active participant? Urology 2004, 64(6 Suppl 1):7-11.
    • (2004) Urology , vol.64 , Issue.6 SUPPL. 1 , pp. 7-11
    • De Groat, W.C.1
  • 8
    • 0027283961 scopus 로고
    • Relationship of symptoms of prostatism to commonly used physiological and anatomical measures of the severity of benign prostatic hyperplasia
    • Barry MJ, Cockett ATK, Holtgrewe HL, et al.: Relationship of symptoms of prostatism to commonly used physiological and anatomical measures of the severity of benign prostatic hyperplasia. J Urol 1993, 150:351-358.
    • (1993) J Urol , vol.150 , pp. 351-358
    • Barry, M.J.1    Cockett, A.T.K.2    Holtgrewe, H.L.3
  • 9
    • 0031923390 scopus 로고    scopus 로고
    • Relationships between lower urinary tract symptoms and bladder outlet obstruction: Results from the ICS-"BPH" study
    • de la Rosette JJ, Witjes WP, Schaefer W, et al.: Relationships between lower urinary tract symptoms and bladder outlet obstruction: results from the ICS-"BPH" study. Neurourol Urodyn 1998, 17:99-108.
    • (1998) Neurourol Urodyn , vol.17 , pp. 99-108
    • De La Rosette, J.J.1    Witjes, W.P.2    Schaefer, W.3
  • 10
    • 8144221209 scopus 로고    scopus 로고
    • Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder
    • Lee JY, Kim HW, Lee SJ: Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder. BJU Int 2004, 94:817-820.
    • (2004) BJU Int , vol.94 , pp. 817-820
    • Lee, J.Y.1    Kim, H.W.2    Lee, S.J.3
  • 11
    • 0034934163 scopus 로고    scopus 로고
    • Detrusor instability in men: Correlation of lower urinary tract symptoms with urodynamic findings
    • Hyman MJ, Groutz A, Blaivas JG: Detrusor instability in men: correlation of lower urinary tract symptoms with urodynamic findings. J Urol 2001, 166:550-552.
    • (2001) J Urol , vol.166 , pp. 550-552
    • Hyman, M.J.1    Groutz, A.2    Blaivas, J.G.3
  • 12
    • 0037454370 scopus 로고    scopus 로고
    • Effectiveness of anticholinergic drugs compared with placebo in the treatment of overactive bladder: Systematic review
    • Herbison P, Hay-Smith J, Ellis G, et al.: Effectiveness of anticholinergic drugs compared with placebo in the treatment of overactive bladder: systematic review. BMJ 2004, 326:841-844.
    • (2004) BMJ , vol.326 , pp. 841-844
    • Herbison, P.1    Hay-Smith, J.2    Ellis, G.3
  • 13
    • 0023266510 scopus 로고
    • Detrusor hyperactivity with impaired contractile function: An unrecognized but common cause of incontinence in elderly patients
    • Resnick NM, Yalla SV: Detrusor hyperactivity with impaired contractile function: an unrecognized but common cause of incontinence in elderly patients. JAMA 1987, 257:3076-3081.
    • (1987) JAMA , vol.257 , pp. 3076-3081
    • Resnick, N.M.1    Yalla, S.V.2
  • 14
    • 0034027586 scopus 로고    scopus 로고
    • Combined behavioral and drug therapy for urge incontinence in older women
    • Burgio KL, Locher JL, Goode PS: Combined behavioral and drug therapy for urge incontinence in older women. J Am Geriatr Soc 2000, 48:370-374.
    • (2000) J Am Geriatr Soc , vol.48 , pp. 370-374
    • Burgio, K.L.1    Locher, J.L.2    Goode, P.S.3
  • 15
    • 0038286511 scopus 로고    scopus 로고
    • Combination treatment with an alpha-blocker plus an anticholinergic for bladder outlet obstruction: A prospective, randomized, controlled study
    • Athanasopoulos A, Gyftopoulos K, Giannitsas K, et al.: Combination treatment with an alpha-blocker plus an anticholinergic for bladder outlet obstruction: a prospective, randomized, controlled study. J Urol 2003, 169:2253-2256. This was the first randomized study to evaluate the efficacy of treatment with α-blockade and anticholinergic therapy in men with BOO and LUTS. Contrary to previous concerns regarding the risk of urinary retention in patients' anticholinergic treated BPH, there were no episodes of urinary retention in the placebo or tolterodine groups. The tolterodine group had better overall symptom improvement in addition to the moderate urodynamic benefits.
    • (2003) J Urol , vol.169 , pp. 2253-2256
    • Athanasopoulos, A.1    Gyftopoulos, K.2    Giannitsas, K.3
  • 16
    • 7544223327 scopus 로고    scopus 로고
    • Alpha-1 adrenoreceptor subtype selectivity and lower urinary tract symptoms
    • Schwinn DA, Price DT, Perinchery N: Alpha-1 adrenoreceptor subtype selectivity and lower urinary tract symptoms. Mayo Clin Proc 2004, 79:1423-1434. This is an extensive review on the title topic.
    • (2004) Mayo Clin Proc , vol.79 , pp. 1423-1434
    • Schwinn, D.A.1    Price, D.T.2    Perinchery, N.3
  • 17
    • 0036074656 scopus 로고    scopus 로고
    • Correlations of urodynamic changes with changes in symptoms and well-being after transurethral resection of the prostate
    • Van Venrooij GE, Van Melick HH, Eckhardt MD, et al.: Correlations of urodynamic changes with changes in symptoms and well-being after transurethral resection of the prostate. J Urol 2002, 168:605-609.
    • (2002) J Urol , vol.168 , pp. 605-609
    • Van Venrooij, G.E.1    Van Melick, H.H.2    Eckhardt, M.D.3
  • 18
    • 4544358072 scopus 로고    scopus 로고
    • Delayed treatment of bladder outlet obstruction after sling surgery: Association with irreversible bladder dysfunction
    • Leng WW, Davies BJ, Tarin T, et al.: Delayed treatment of bladder outlet obstruction after sling surgery: association with irreversible bladder dysfunction. J Urol 2004, 172:1379-1381.
    • (2004) J Urol , vol.172 , pp. 1379-1381
    • Leng, W.W.1    Davies, B.J.2    Tarin, T.3
  • 19
    • 31744442106 scopus 로고    scopus 로고
    • Overactive bladder: A better understanding of pathophysiology, diagnosis, and management
    • Wein AJ, Rackley RR: Overactive bladder: a better understanding of pathophysiology, diagnosis, and management. J Urol 2006, 175:S5-S10.
    • (2006) J Urol , vol.175
    • Wein, A.J.1    Rackley, R.R.2
  • 20
    • 32044449411 scopus 로고    scopus 로고
    • Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction
    • Abrams P, Kaplan S, De Koning Gans HJ, Millard R: Safety and tolerability of tolterodine for the treatment of overactive bladder in men with bladder outlet obstruction. J Urol, 2006, 175:999-1004.
    • (2006) J Urol , vol.175 , pp. 999-1004
    • Abrams, P.1    Kaplan, S.2    De Koning Gans, H.J.3    Millard, R.4
  • 21
    • 0038286511 scopus 로고    scopus 로고
    • Combination treatment with an alpha-blocker plus an anticholinergic for bladder outlet obstruction: A prospective, randomized, controlled study
    • Athanasopoulos A, Gyftopoulos K, Giannitsas K, et al.: Combination treatment with an alpha-blocker plus an anticholinergic for bladder outlet obstruction: a prospective, randomized, controlled study. J Urol 2003, 169:2253-2256.
    • (2003) J Urol , vol.169 , pp. 2253-2256
    • Athanasopoulos, A.1    Gyftopoulos, K.2    Giannitsas, K.3
  • 22
    • 27744523690 scopus 로고    scopus 로고
    • Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia
    • Kaplan SA, Walmsley K, Te AE: Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia. J Urol 2005, 174:2273-2275.
    • (2005) J Urol , vol.174 , pp. 2273-2275
    • Kaplan, S.A.1    Walmsley, K.2    Te, A.E.3
  • 23
    • 0032829435 scopus 로고    scopus 로고
    • Once-daily controlled versus immediate-release oxybutynin chloride for urge urinary incontinence
    • Anderson RU, Mobley D, Blank B, et al.: Once-daily controlled versus immediate-release oxybutynin chloride for urge urinary incontinence. J Urol 1999, 161:1809-1812.
    • (1999) J Urol , vol.161 , pp. 1809-1812
    • Anderson, R.U.1    Mobley, D.2    Blank, B.3
  • 24
    • 0033010540 scopus 로고    scopus 로고
    • Tolterodine in the treatment of overactive bladder: Analysis of the pooled phase II efficacy and safety data
    • Larsson G, Hallen B, Nilvebrant L: Tolterodine in the treatment of overactive bladder: analysis of the pooled phase II efficacy and safety data. Urology 1999, 53:990-998.
    • (1999) Urology , vol.53 , pp. 990-998
    • Larsson, G.1    Hallen, B.2    Nilvebrant, L.3
  • 25
    • 18544379289 scopus 로고    scopus 로고
    • A pooled analysis of three phase III studies to investigate the efficacy, tolerability and safety of darifenacin, a muscarinic M3 selective receptor antagonist, in the treatment of overactive bladder
    • Chapple C, Steers W, Norton P, et al.: A pooled analysis of three phase III studies to investigate the efficacy, tolerability and safety of darifenacin, a muscarinic M3 selective receptor antagonist, in the treatment of overactive bladder. BJU Int 2005, 85:993-1001.
    • (2005) BJU Int , vol.85 , pp. 993-1001
    • Chapple, C.1    Steers, W.2    Norton, P.3
  • 26
    • 0024409752 scopus 로고
    • Neural stimulation for control of voiding dysfunction: A preliminary report in 22 patients with serious neuropathic voiding disorders
    • Tanagho EA, Schmidt RA, Orvis BR: Neural stimulation for control of voiding dysfunction: a preliminary report in 22 patients with serious neuropathic voiding disorders. J Urol 1989, 142:340-345.
    • (1989) J Urol , vol.142 , pp. 340-345
    • Tanagho, E.A.1    Schmidt, R.A.2    Orvis, B.R.3
  • 27
    • 0034747671 scopus 로고    scopus 로고
    • Efficacy of sacral nerve stimulation for urinary retention: Results 18 months after implantation
    • Jonas U, Fowler CJ, Chancellor MB, et al.: Efficacy of sacral nerve stimulation for urinary retention: results 18 months after implantation. J Urol 2001, 165:15-19.
    • (2001) J Urol , vol.165 , pp. 15-19
    • Jonas, U.1    Fowler, C.J.2    Chancellor, M.B.3
  • 28
    • 32044459070 scopus 로고    scopus 로고
    • Sacral neuromodulation in women with idiopathic detrusor overactivity incontinence: Decreased overactivity but unchanged bladder contraction strength and urethral resistance during voiding
    • Groen J, Ruud Bosch J, van Mastrigt R: Sacral neuromodulation in women with idiopathic detrusor overactivity incontinence: decreased overactivity but unchanged bladder contraction strength and urethral resistance during voiding. J Urol 2006, 175:1005-1009.
    • (2006) J Urol , vol.175 , pp. 1005-1009
    • Groen, J.1    Ruud Bosch, J.2    Van Mastrigt, R.3
  • 29
    • 33644751678 scopus 로고    scopus 로고
    • Efficacy of sacral neuromodulation for symptomatic treatment of refractory urinary urge incontinence
    • Latini JM, Alipour M, Kreder KJ: Efficacy of sacral neuromodulation for symptomatic treatment of refractory urinary urge incontinence. Urology 2006, 67:550-553.
    • (2006) Urology , vol.67 , pp. 550-553
    • Latini, J.M.1    Alipour, M.2    Kreder, K.J.3
  • 30
    • 0031664455 scopus 로고    scopus 로고
    • Intrasphincteric injection of botulinum toxin is effective in long-term treatment of esophageal achalasia
    • Annese V, Basciani M, Borrelli O, et al.: Intrasphincteric injection of botulinum toxin is effective in long-term treatment of esophageal achalasia. Muscle Nerve 1998, 21:1540-1542.
    • (1998) Muscle Nerve , vol.21 , pp. 1540-1542
    • Annese, V.1    Basciani, M.2    Borrelli, O.3
  • 31
    • 31944439844 scopus 로고    scopus 로고
    • Non-neuronal cholinergic system in human bladder urothelium
    • Yoshida M, Inadome A, Maeda Y: Non-neuronal cholinergic system in human bladder urothelium. Urology 2006, 67:425-430.
    • (2006) Urology , vol.67 , pp. 425-430
    • Yoshida, M.1    Inadome, A.2    Maeda, Y.3
  • 32
    • 33644853798 scopus 로고    scopus 로고
    • Proposed mechanism for the efficacy of injected botulinum toxin in the treatment of human detrusor overactivity
    • Apostolidis A, Dasgupta P, Fowler CJ: Proposed mechanism for the efficacy of injected botulinum toxin in the treatment of human detrusor overactivity. Euro Urol 2006, 49:644-650.
    • (2006) Euro Urol , vol.49 , pp. 644-650
    • Apostolidis, A.1    Dasgupta, P.2    Fowler, C.J.3
  • 33
    • 0033870343 scopus 로고    scopus 로고
    • Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: A new alternative to anticholinergic drugs? Preliminary results
    • Schurch B, Stohrer M, Kramer G, et al.: Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol 2000, 164:692-697.
    • (2000) J Urol , vol.164 , pp. 692-697
    • Schurch, B.1    Stohrer, M.2    Kramer, G.3
  • 34
    • 20444459051 scopus 로고    scopus 로고
    • Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: Results of a single treatment, randomized, placebo controlled 6-month study
    • Schurch B, de Seze M, Denys P, et al.: Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study. J Urol 2005, 174:196-200. This is the first randomized study in patients with urinary incontinence caused by DO. It demonstrates the efficacy and tolerability of BTX. This study provides important data in support of the use of BTX-A injection in DO patients.
    • (2005) J Urol , vol.174 , pp. 196-200
    • Schurch, B.1    De Seze, M.2    Denys, P.3
  • 35
    • 33744552465 scopus 로고    scopus 로고
    • Experience with 100 cases treated with botulinum-A toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics
    • Schmid DM, Sauermann P, Werner M, et al.: Experience with 100 cases treated with botulinum-A toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics. J Urol 2006, 176:177-185.
    • (2006) J Urol , vol.176 , pp. 177-185
    • Schmid, D.M.1    Sauermann, P.2    Werner, M.3
  • 36
    • 33744511650 scopus 로고    scopus 로고
    • The effect of botulinum-A toxin in incontinent children with therapy resistant overactive detrusor
    • Hoebeke P, De Caestecker K, Vande Walle J, et al.: The effect of botulinum-A toxin in incontinent children with therapy resistant overactive detrusor. J Urol 2006, 176:328-330.
    • (2006) J Urol , vol.176 , pp. 328-330
    • Hoebeke, P.1    De Caestecker, K.2    Vande Walle, J.3
  • 37
    • 26444571818 scopus 로고    scopus 로고
    • Simplified bladder botulinum toxin delivery technique using flexible cystoscope and 10 sites of injection
    • Smith CP, Chancellor MB: Simplified bladder botulinum toxin delivery technique using flexible cystoscope and 10 sites of injection. J Endourol 2005, 19:880-882.
    • (2005) J Endourol , vol.19 , pp. 880-882
    • Smith, C.P.1    Chancellor, M.B.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.